VanEck非必需消費品TruSector主動型ETF TRUD 深 滬
等待開盤 08-10 09:30:00 美东时间
26.8557
+0.377
+1.42%
華盛通- 最 高26.98
- 今 開26.98
- 成交量 1.74万股
- 最 低 26.80
- 昨 收 26.4787
- 總市值 5827.69万
- 52周最高 27.4386
- 市盈率 靜 --
- 換手率 0.80%
- 52周最低 22.7981
- 委 比 -5.88%
- 總股本 217.00万
- 歷史最高 27.4181
- 量 比 1.12
- 振 幅 0.68%
- 歷史最低 22.7981
- 每 手 1
- 風險率 0.89%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Amazon earnings preview: Will AWS reacceleration justify the capex binge?
Amazon (AMZN) is lined up to report second quarter earnings on July 30 after the market closes. Investors will be looking for proof that AWS growth is reaccelerating, retail margins are holding up, an...
07-25 19:05
VanEck推出四只新ETF，TruSector系列实现GICS全行业覆盖
资产管理公司VanEck推出四只新的TruSector系列ETF，分别为能源（TRUN）、公用事业（TRUU）、房地产（TRUR）和材料（TRUM）板块基金...
07-08 22:34
Merck And Gilead Discontinue Phase 3 KEYNOTE-D46/EVOKE-03 Trial After Trodelvy–KEYTRUDA Combination Fails To Achieve Statistically Significant Progression-Free Survival Benefit In First-Line Metastatic NSCLC
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Gilead Sciences, Inc. (NASDAQ:GILD) today announced the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study investigating Gilead's
06-09 04:31
FDA Approves Agilent Technologies' Expanded Use Of PD-L1 IHC 22C3 pharmDx, Code GE006,
Approval expands PD-L1 testing onto an automated workflow to support treatment decisions with KEYTRUDA® (pembrolizumab)¹,²
06-03 04:17
Moderna And Merck Present 5-Year Data For Intismeran Autogene in Combination With KEYTRUDA In Patients With High-Risk Stage III/IV Melanoma
At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of recurrence or death and a
06-01 20:05
European Medicines Agency's Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Approval Of Merck's KEYTRUDA In Combination With Padcev To Treat Resectable Muscle-Invasive Bladder Cancer
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending
05-22 19:57
